Insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial
Marian L. Neuhouser(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alan R. Kristal(Fred Hutch Cancer Center), Jeannette M. Schenk(Fred Hutch Cancer Center), Ian M. Thompson(The University of Texas at San Antonio Health Science Center), David F. Penson(Geriatric Research Education and Clinical Center), Catherine M. Tangen(American Urological Association), Phyllis J. Goodman(Translational Research Institute), YoonJu Song(The Catholic University of Korea Bucheon St. Mary's Hospital), Michaël Pollak(McGill University)
Cited by 56
Related Papers
Frailty in Older Adults: Evidence for a Phenotype
|The Journals of Gerontology Series A|2001|24.4k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k
Circulating concentrations of insulin-like growth factor I and risk of breast cancer
|The Lancet|1998|1.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k